Impact of Empirical Antibiotic Regimens on Mortality in Neutropenic Patients with Bloodstream Infection Presenting with Septic Shock
We analyzed risk factors for mortality in febrile neutropenic patients with bloodstream infections (BSI) presenting with septic shock and assessed the impact of empirical antibiotic regimens. A multicenter retrospective study (2010 to 2019) of two prospective cohorts compared BSI episodes in patients with or without septic shock. Multivariate analysis was performed to identify independent risk factors for mortality in episodes with septic shock. Of 1,563 patients with BSI, 257 (16%) presented with septic shock. Those patients with septic shock had higher mortality than those without septic shock (55% versus 15%, P < 0.001). Gram-negative bacilli caused 81% of episodes with septic shock, Gram-positive cocci caused 22%, and Candida species caused 5%. Inappropriate empirical antibiotic treatment (IEAT) was administered in 17.5% of septic shock episodes. Empirical β-lactam combined with other active antibiotics was associated with the lowest mortality observed. When amikacin was the only active antibiotic, mortality was 90%. Addition of empirical specific Gram-positive coverage had no impact on mortality. Mortality was higher when IEAT was administered (76% versus 51%, P = 0.002). Age of >70 years (odds ratio [OR], 2.3; 95% confidence interval [CI], 1.2 to 4.7), IEAT for Candida spp. or Gram-negative bacilli (OR, 3.8; 95% CI, 1.3 to 11.1), acute kidney injury (OR, 2.6; 95% CI, 1.4 to 4.9), and amikacin as the only active antibiotic (OR, 15.2; 95% CI, 1.7 to 134.5) were independent risk factors for mortality, while the combination of β-lactam and amikacin was protective (OR, 0.32; 95% CI, 0.18 to 0.57). Septic shock in febrile neutropenic patients with BSI is associated with extremely high mortality, especially when IEAT is administered. Combination therapy including an active β-lactam and amikacin results in the best outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:66 |
|---|---|
| Enthalten in: |
Antimicrobial agents and chemotherapy - 66(2022), 2 vom: 15. Feb., Seite e0174421 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chumbita, Mariana [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 22.03.2022 Date Revised 16.08.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1128/AAC.01744-21 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333804368 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333804368 | ||
| 003 | DE-627 | ||
| 005 | 20231225222411.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/AAC.01744-21 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1112.xml |
| 035 | |a (DE-627)NLM333804368 | ||
| 035 | |a (NLM)34843387 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chumbita, Mariana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of Empirical Antibiotic Regimens on Mortality in Neutropenic Patients with Bloodstream Infection Presenting with Septic Shock |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.03.2022 | ||
| 500 | |a Date Revised 16.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a We analyzed risk factors for mortality in febrile neutropenic patients with bloodstream infections (BSI) presenting with septic shock and assessed the impact of empirical antibiotic regimens. A multicenter retrospective study (2010 to 2019) of two prospective cohorts compared BSI episodes in patients with or without septic shock. Multivariate analysis was performed to identify independent risk factors for mortality in episodes with septic shock. Of 1,563 patients with BSI, 257 (16%) presented with septic shock. Those patients with septic shock had higher mortality than those without septic shock (55% versus 15%, P < 0.001). Gram-negative bacilli caused 81% of episodes with septic shock, Gram-positive cocci caused 22%, and Candida species caused 5%. Inappropriate empirical antibiotic treatment (IEAT) was administered in 17.5% of septic shock episodes. Empirical β-lactam combined with other active antibiotics was associated with the lowest mortality observed. When amikacin was the only active antibiotic, mortality was 90%. Addition of empirical specific Gram-positive coverage had no impact on mortality. Mortality was higher when IEAT was administered (76% versus 51%, P = 0.002). Age of >70 years (odds ratio [OR], 2.3; 95% confidence interval [CI], 1.2 to 4.7), IEAT for Candida spp. or Gram-negative bacilli (OR, 3.8; 95% CI, 1.3 to 11.1), acute kidney injury (OR, 2.6; 95% CI, 1.4 to 4.9), and amikacin as the only active antibiotic (OR, 15.2; 95% CI, 1.7 to 134.5) were independent risk factors for mortality, while the combination of β-lactam and amikacin was protective (OR, 0.32; 95% CI, 0.18 to 0.57). Septic shock in febrile neutropenic patients with BSI is associated with extremely high mortality, especially when IEAT is administered. Combination therapy including an active β-lactam and amikacin results in the best outcomes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a bacteremia | |
| 650 | 4 | |a empirical treatment | |
| 650 | 4 | |a mortality | |
| 650 | 4 | |a neutropenia | |
| 650 | 4 | |a shock | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a Puerta-Alcalde, Pedro |e verfasserin |4 aut | |
| 700 | 1 | |a Gudiol, Carlota |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia-Pouton, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Laporte-Amargós, Júlia |e verfasserin |4 aut | |
| 700 | 1 | |a Ladino, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Albasanz-Puig, Adaia |e verfasserin |4 aut | |
| 700 | 1 | |a Helguera, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Bergas, Alba |e verfasserin |4 aut | |
| 700 | 1 | |a Grafia, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Sastre, Enric |e verfasserin |4 aut | |
| 700 | 1 | |a Suárez-Lledó, María |e verfasserin |4 aut | |
| 700 | 1 | |a Durà, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Jordán, Carlota |e verfasserin |4 aut | |
| 700 | 1 | |a Marco, Francesc |e verfasserin |4 aut | |
| 700 | 1 | |a Condom, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Castro, Pedro |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez, Jose A |e verfasserin |4 aut | |
| 700 | 1 | |a Mensa, Josep |e verfasserin |4 aut | |
| 700 | 1 | |a Soriano, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Carratalà, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia-Vidal, Carolina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Antimicrobial agents and chemotherapy |d 1972 |g 66(2022), 2 vom: 15. Feb., Seite e0174421 |w (DE-627)NLM000026506 |x 1098-6596 |7 nnns |
| 773 | 1 | 8 | |g volume:66 |g year:2022 |g number:2 |g day:15 |g month:02 |g pages:e0174421 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/AAC.01744-21 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 66 |j 2022 |e 2 |b 15 |c 02 |h e0174421 | ||